<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186053</url>
  </required_header>
  <id_info>
    <org_study_id>FWT2017-ZX004</org_study_id>
    <nct_id>NCT03186053</nct_id>
  </id_info>
  <brief_title>Sodium Creatine Phosphate in Heart Valve Surgery</brief_title>
  <official_title>Cardioprotective Effects of Sodium Creatine Phosphate in Valve Surgery: A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effect of intraoperative sodium creatine phosphate on myocardial protection in
      patients undergoing valve surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To explore the effect of intraoperative sodium creatine phosphate on myocardial
      protection in patients undergoing valve surgery Methods: 250 patients undergoing valve
      surgery were randomly divided into experimental group and control group. 5g creatine
      phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients
      were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h
      (10 ml / h). The control group was treated with saline in the same manner. The cTnI level was
      measured at the corresponding time points. Hemodynamic indexes and postoperative
      complications were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum cardiac troponin I(cTnI)</measure>
    <time_frame>within 24 hours after aortic declamping</time_frame>
    <description>serum cardiac troponin I(cTnI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>death rate in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>defintion by surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood filtration of kidney failure</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>need for dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extracorporeal membrane oxygenation (ECMO) or intraaortic balloon counterpulsation (IABP) support</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>heart failure requires mechanical assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mechanical ventilation time</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrhythmia</measure>
    <time_frame>within 30 postoperative days</time_frame>
    <description>Atrial fibrillation or Ventricular fibrillation or Ventricular tachycardia requiring drug treatments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart Valve Diseases</condition>
  <arm_group>
    <arm_group_label>sodium creatine phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group was treated with saline in the same manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium creatine phosphate</intervention_name>
    <description>sodium creatine phosphate .Loading dose followed by continuous infusion in operation</description>
    <arm_group_label>sodium creatine phosphate</arm_group_label>
    <other_name>Neoton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>.Loading dose followed by continuous infusion in operation</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  valvular disease patients requiring valvular replacement or repair surgery with
             cardiopulmonary bypass(CPB)

        Exclusion Criteria:

          -  thoracoscopic valve surgery

          -  other organ dysfunction: such as cancer, organ failure, severe anemia, infection

          -  patients with mental disorders

          -  coagulopathy, active ulcer, ischemic or hemorrhagic stroke (within 6 months), trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guyan WANG, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of anesthesiology,Fuwai hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guyan WANG, M.D.</last_name>
    <phone>+86-13910985139</phone>
    <email>13910985139@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongrong FANG, M.D</last_name>
    <phone>+86-15001391329</phone>
    <email>fangzhongrong@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology ,Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS and PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guyan WANG, M.D.</last_name>
      <phone>+86-13910985139</phone>
      <email>13910985139@163.com</email>
    </contact>
    <investigator>
      <last_name>Guyan WANG, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guyan Wang, M.D.</last_name>
      <phone>86-10-88398082</phone>
      <email>13910985139@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Guyan Wang</investigator_full_name>
    <investigator_title>The Chief of Infection-Control Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phosphocreatine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

